LYZ and chronic kidney disease: Using the study by Glorieux et al. 37 as a basis, involving high resolution LC-MS/MS analysis of plasma proteome from patients with CKD and reporting on associations to outcome, in combination to the aforementioned criteria, the tested panel includes B2M38–46 and SERPINF147–50, having been largely studied in CKD and serving as positive controls for the approach, as well as AMBP, LYZ, HBB, and IGHA1 with some earlier reported associations37, nevertheless not been validated yet in association with disease progression via absolute quantification.